Predicting Difference in Mean Survival Time from Reported Hazard Ratios for Cancer Patients

Background. Gain in mean survival time from new cancer treatments is a core component of cost-effectiveness analyses frequently used by payers for reimbursement decisions. Due to limited follow-up time, clinical trials rarely report this measure, whereas they often report hazard ratios comparing treatment groups. Aim. We aimed to explore the empirical relationship between gain in mean survival time and the hazard ratio for cancer patients....